On Thursday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.37% to $31.84.
Pfizer declared that it has accomplished the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
“The addition of Nimenrix and Mencevax assists us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These vaccines add high-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products comprise Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. \
Shares of Merck & Co., Inc. (NYSE:MRK), inclined 0.24% to $49.51, during its last trading session.
Merck & Co., known as MSD outside the United States and Canada, and DNAtrix recently declared they have reached an oncology clinical study partnershipto evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.
DNX-2401 is a conditionally replicative oncolytic adenovirus designed to specifically target cells defective in the Retinoblastoma (Rb) pathway, which is present in many cancers. Several DNX-2401 clinical studies have demonstrated a favorable safety profile and strong tumor-killing potential in patients with recurrent glioblastoma. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. KEYTRUDA is presently approved in the United States for certain types of advanced metastatic melanoma.
The agreement is between DNAtrix and Merck, through a partner. Additional details of the partnership were not revealed.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures.
Shares of Noble Corp plc (NYSE:NE), declined -2.75% to $10.61, during its last trading session.
Noble Corporation’s VP Bernie G. Wolford bought 10,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was purchased at an average price of $10.82 per share, for a total transaction of $108,200.00. Following the purchase, the vice president now owns 49,916 shares of the company’s stock, valued at about $540,091.12. The transaction was revealed in a filing with the SEC
Noble Corporation plc operates as an offshore drilling contractor for the oil and gas industry worldwide. It owns and operates a fleet of mobile offshore drilling units. As of December 31, 2014, the company operated a fleet of 15 jackups, 9 drillships, and 8 semisubmersibles, counting 1 high-specification, harsh environment jackup under construction.
Finally, Sarepta Therapeutics Inc (NASDAQ:SRPT), ended its last trade with 22.23% gain, and closed at $39.28.
Sarepta Therapeutics declared a four year collaborative research agreement to establish the Sarepta Translational Laboratory with Murdoch University, Perth, Western Australia. The Laboratory, led by Murdoch University professors Steve Wilton, Ph.D. and Sue Fletcher, Ph.D., will explore the applicability of the Company’s phosphorodiamidate morpholino oligomer (PMO) technology for disease targets beyond Duchenne muscular dystrophy (DMD), such as cystic fibrosis and spinal muscular atrophy.
The agreement provides the Murdoch University researchers with access to Sarepta’s PMO platform technology, in addition to additional funding for researchers and materials. The initial project for the partnership is anticipated to target multiple sclerosis. As part of the collaborative agreement, Sarepta will have exclusive rights to license technology and/or products resulting from the research projects.
Murdoch University’s Acting Vice Chancellor Professor Andrew Taggart noted that the agreement with Sarepta allows the University’s laboratory to become a pipeline of drug development, and the Sarepta association will facilitate getting the drugs from the laboratory to clinical trials.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
